Ignite Creation Date:
2024-07-17 @ 11:09 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06481566
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-06-20
Brief Title:
Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy SBRT in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation a Single-arm Open-label Clinical Trial
Sponsor:
Chongqing University Cancer Hospital
Organization:
Chongqing University Cancer Hospital
Organization Data
Organization:
Chongqing University Cancer Hospital
Class:
OTHER
Study ID:
AlmoSABR
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Chongqing University Cancer Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Wei Zhou
Responsible Party Title:
Derector of Department of Radiation Oncology
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Chongqing University Cancer Hospital
Old Name:
None
Old Organization:
None